TNFRSF4 and Alzheimer disease: A humanized antibody GBR830 targeting OX40, a costimulatory molecule expressed mainly on T cell subtypes, led to significantly lower clinical severity scores and decreased cutaneous AD gene signatures (Th1 signaling-IFN-γ and CXCL10, Th2 signaling-IL-31, CCL11, and CCL17, Th17/Th22 signaling-IL-23p19, IL-8, and S100A12) versus placebo (65).